Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Ecole Normale Superieure

College De France

Sorbonne Université

Ariel Di Nardo

Alain Prochiantz

Kenneth Lee Moya

Marine Beurdeley

Takao Hensch

Karen Arnaud

Solange Lavielle

Damien Testa

Jean-Maurice Mallet

Rodrigue Marquant

Takao K Hensch

The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.

Ligand controling interaction between gags with their effector molecules and use thereof

The disclosure provides a method of delivering a polypeptide molecule to an Otx2 target cell, including contacting the target cell with a chimeric polypeptide having (i) a targeting peptide consisting of SEQ ID NO: 2 and (ii) the polypeptide molecule.

Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide

The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of &#x3b2;APP or of the activity of the A&#x3b2; peptide in the choroid plexus.

Inhibition of the synthesis of beta-app or the activity of the A-&#x3b2; peptide in the choroid plexus

Growing community of inventors

Palaiseau, France

Ariel Di Nardo